Digistain

Pioneering Breast Cancer Diagnostics for a Healthier Tomorrow

Y CombinatorSummer 2021ActiveHealthcareDiagnosticsMedical Devices

What they do

Problem

Most breast cancer patients cannot access timely, affordable genomic testing to guide post-surgery treatment decisions, leading to unnecessary chemotherapy.

Solution

Digistain provides a diagnostic technology that predicts breast cancer genomic risk from tissue analysis as a faster, lower-cost alternative to traditional genomic testing.

Who it's for

Hospitals and pathology labs (clinicians treating breast cancer patients) use it to inform treatment decisions.

Founders

Hemmel Amrania

Founder

Hemmel Amrania Ph.D, CEO has previously scaled several 7 figure businesses both in therapeutics and diagnostics. As a doctoral researcher he was awarded the Outstanding Research Prize at Imperial College London. He has also won several UK business awards including the Innovation & Entrepreneurship Challenge Imperial College and the Climate KIC Competition held by the Mayor of London. For Digistain he spear-headed the research out of the lab all the way through to clinical trials.

Chris Phillips

Founder

Chris is an Imperial College Physics Professor, researching into photovoltaics, and biomedical imaging. He's spent the last few years, with Hemmel Amrania, developing the Digistain cancer diagnosis technology with Imperial medics. He has won a number of prizes and has explained his research on invisibility caused by quantum optical effects to comedy legend Cleese on TV. He once rowed 500 miles non-stop from London to Paris. See https://en.wikipedia.org/wiki/Chris_Phillips_(professor)